The global bradycardia market is segmented on the basis of two parameters: the types of disease and therapeutic treatments. On the basis of types of disease, it is divided into ventricular, atrioventricular nodal, atrial, and infantile bradycardia.
Albany, NY -- (SBWIRE) -- 02/22/2017 -- Bradycardia, also known as, bradyarrhythmia is one of the most important cardiac diseases. Bradycardia is a medically abnormal state of heart in which the pulse rate (heart beats) is less than 60 beats per minute (BPM). Bradycardia, in simplest sense, is a condition, in which heart shows decline in its efficiency. If heart shows around 50 BPM, it brings symptoms like tiredness, weakness, fatigue, dizziness and skin fainting. This is considered as symptom of heart diseases. Further, if the heart rate is less than 40 BPM, it must be taken seriously to treat.
Bradycardia is caused due to various cardiac and non-cardiac symptoms. Non-cardiac symptoms mainly include abusive drugs consumption, endocrine and metabolic dysfunctioning, neurologic factors and electrolyte imbalance. Further, prolonged sleep and autoimmune response are the other major causes. Whereas, cardiac caused include valvular and vascular heart diseases, ischemic heart disease and cardiac arrhythmia. Bradycardia is usually diagnosed by pulse rate monitors and ECG.
Request a Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=509
Global Bradycardia Market: Summary
The global bradycardia market is segmented on the basis of two parameters: the types of disease and therapeutic treatments. On the basis of types of disease, it is divided into ventricular, atrioventricular nodal, atrial, and infantile bradycardia. On the basis of drugs and therapy, the market is segmented into epinephrine, dopamine, adrenaline, levsin, and atropine. Hypothyroidism treatment is also useful in bradycardia, which includes liotix, liothyronine, and levothyroxine. Although drug therapies are largely available, the usual and core therapeutic aspect is pacemaker installation. Pacemakers are considered as the prime therapy for bradycardia and arrhythmia. Drugs and pacemaker therapies are used specifically when the heart slows down to lower than 50 BPM.
The global bradycardia market is segmented on the basis of geography, into North America, Europe, Asia-Pacific and the rest of the world. The North American region has so far been the dominant one in the global bradycardia market, owing to a fast rate of growth in its number of bradycardia patients. On the other hand, Asia-Pacific and RoW regions are showing a lot of promise for growth over the coming years, owing to a rise in awareness of diagnostics and monitoring in cardiac diseases and the growth of medical infrastructure.
Request for TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=509
Global Bradycardia Market: Trends and Prospects
The global bradycardia market is expected to grow are a very fast pace during between 2014 and 2020, likely to be driven by factors such as the increasing prevalence of cardiac diseases and bradycardia, extensive R&D efforts, and a rise in awareness of cardiac disease monitoring. Other factors such as the evolution of medical and healthcare infrastructure and growth in medical expenditure in emerging economies are also promoting the global bradycardia market's growth.
According to a report published by the U.S. Centers for Disease Control and Prevention (CDC) in 2008, the prevalence of bradycardia was in close to 15% of males and 7% of females from the total U.S. population. Extensive R&D practices are consequently being conducted, further benefittin the global bradycardia market. Considering the growth opportunities in the market, pharmaceutical companies and medical devices manufacturers have taken a serious part in the bradycardia R&D practices. However, key restraints to the global bradycardia market include lack of awareness and tendency of ignorance towards the symptoms, especially in emerging economies from APAC, The MEA, and Latin America, and the generally high cost of pacemaker-based treatments.
Read Complete Report @ https://www.tmrresearch.com/bradycardia-market
Key players operating in the global bradycardia market include Medtronic, Inc., Boston Scientific Corporation, St. Jude Medical, Inc., Mayo Clinic, and UMC Utrecht Holding BV.
About TMR Research
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
Our savvy custom-built reports span a gamut of industries such as pharmaceuticals, chemicals and metals, food and beverages, and technology and media, among others. With actionable insights uncovered through in-depth research of the market, we try to bring about game-changing success for our clients.